Free Trial

Champions Oncology Q3 2024 Earnings Report

Champions Oncology EPS Results

Actual EPS
-$0.19
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Champions Oncology Revenue Results

Actual Revenue
$12.02 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Champions Oncology Announcement Details

Quarter
Q3 2024
Time
N/A

Conference Call Resources

Trump’s Sending THIS Crypto Higher on Purpose (Ad)

Discover the coin set to explode before 2025! Trump could trigger THIS crypto coin…

YES, I WANT THE #1 CRYPTO NOW

Champions Oncology Earnings Headlines

Trump’s Sending THIS Crypto Higher on Purpose
Discover the coin set to explode before 2025! Trump could trigger THIS crypto coin…
Champions Oncology price target raised to $8 from $6 at Craig-Hallum
A Peek at Champions Oncology's Future Earnings
See More Champions Oncology Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Champions Oncology? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Champions Oncology and other key companies, straight to your email.

About Champions Oncology

Champions Oncology (NASDAQ:CSBR) engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. Its technology platform, TumorGraft, is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. It uses its technology to offer solutions to Translational Oncology Solutions, which includes pharmaceutical and biotechnology companies; and Personalized Oncology, which assists physicians in developing personalized treatment options for their cancer patients. The company was founded by James M. Martell and David Sidransky on June 4, 1985 and is headquartered in Hackensack, NJ.

View Champions Oncology Profile

More Earnings Resources from MarketBeat

Upcoming Earnings